Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
QURE Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
QURE Stock 12 Month Forecast
Average Price Target
$40.00
▲(150.16%Upside)
| Highest Price Target$70.00 | Average Price Target$40.00 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$18
Hold
12.57%
Upside
Reiterated
06/07/25
Stifel Nicolaus
$30
Buy
87.62%
Upside
Reiterated
06/05/25
Leerink Partners
$48
Buy
200.19%
Upside
Reiterated
06/03/25
H.C. Wainwright
$70
Buy
337.77%
Upside
Reiterated
06/03/25
William Blair
―
Buy
―
Reiterated
06/02/25
Wells Fargo
$30
Buy
87.62%
Upside
Reiterated
06/02/25
Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), uniQure (NASDAQ: QURE) and UnitedHealth (NYSE: UNH)We note that details of FDA alignment on BLA filing, now backed by meeting minutes, are consistent with prior guidance and represent best-case regulatory path. We also expect 3- yr data in 3Q25 to show benefit in cUHDRS consistent with 2-yr data. QURE announced, following recent Type B meetings and further guidance from FDA, it has reached alignment with FDA on key components of the statistical analysis plan (SAP) and CMC that will support a BLA filing. On program timeline, QURE plans to submit an updated SAP to FDA in 2Q25, initiate a Process Performance Qualification (PPQ) run and report top-line Ph1/2 data per the SAP in 3Q25, hold a pre-BLA meeting w/ FDA in 4Q25, and submit a BLA w/ a request for priority review designation in 1Q26. SAP updates.
TD Cowen
―
Buy
―
Reiterated
05/09/25
RBC Capital
$24
Buy
50.09%
Upside
Reiterated
05/09/25
Chardan Capital
$38
Buy
137.65%
Upside
Initiated
04/01/25
Goldman Sachs
$20→$18
Hold
12.57%
Upside
Reiterated
02/28/25
Mizuho Securities
$7→$20
Hold
25.08%
Upside
Reiterated
12/19/24
Cantor Fitzgerald
$28→$58
Buy
262.73%
Upside
Reiterated
12/10/24
Raymond James
$9.22
Buy
-42.31%
Downside
Reiterated
12/10/24
Guggenheim
$28
Buy
75.11%
Upside
Reiterated
07/09/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$18
Hold
12.57%
Upside
Reiterated
06/07/25
Stifel Nicolaus
$30
Buy
87.62%
Upside
Reiterated
06/05/25
Leerink Partners
$48
Buy
200.19%
Upside
Reiterated
06/03/25
H.C. Wainwright
$70
Buy
337.77%
Upside
Reiterated
06/03/25
William Blair
―
Buy
―
Reiterated
06/02/25
Wells Fargo
$30
Buy
87.62%
Upside
Reiterated
06/02/25
Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), uniQure (NASDAQ: QURE) and UnitedHealth (NYSE: UNH)We note that details of FDA alignment on BLA filing, now backed by meeting minutes, are consistent with prior guidance and represent best-case regulatory path. We also expect 3- yr data in 3Q25 to show benefit in cUHDRS consistent with 2-yr data. QURE announced, following recent Type B meetings and further guidance from FDA, it has reached alignment with FDA on key components of the statistical analysis plan (SAP) and CMC that will support a BLA filing. On program timeline, QURE plans to submit an updated SAP to FDA in 2Q25, initiate a Process Performance Qualification (PPQ) run and report top-line Ph1/2 data per the SAP in 3Q25, hold a pre-BLA meeting w/ FDA in 4Q25, and submit a BLA w/ a request for priority review designation in 1Q26. SAP updates.
TD Cowen
―
Buy
―
Reiterated
05/09/25
RBC Capital
$24
Buy
50.09%
Upside
Reiterated
05/09/25
Chardan Capital
$38
Buy
137.65%
Upside
Initiated
04/01/25
Goldman Sachs
$20→$18
Hold
12.57%
Upside
Reiterated
02/28/25
Mizuho Securities
$7→$20
Hold
25.08%
Upside
Reiterated
12/19/24
Cantor Fitzgerald
$28→$58
Buy
262.73%
Upside
Reiterated
12/10/24
Raymond James
$9.22
Buy
-42.31%
Downside
Reiterated
12/10/24
Guggenheim
$28
Buy
75.11%
Upside
Reiterated
07/09/24
Best Analysts Covering uniQure
1 Month
xxx
Success Rate
11/23 ratings generated profit
Average Return
-2.00%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.83% of your transactions generating a profit, with an average return of -2.00% per trade.
3 Months
xxx
Success Rate
17/38 ratings generated profit
Average Return
+3.56%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.74% of your transactions generating a profit, with an average return of +3.56% per trade.
1 Year
Success Rate
11/18 ratings generated profit
Average Return
+39.86%
reiterated a buy rating 12 days ago
Copying Sami Corwin's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +39.86% per trade.
2 Years
xxx
Success Rate
14/18 ratings generated profit
Average Return
+68.16%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +68.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
QURE Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
11
8
11
17
20
Buy
10
8
7
7
6
Hold
4
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
17
19
24
26
Each month's total comprises the sum of three months' worth of ratings.
QURE Financial Forecast
QURE Stock Forecast FAQ
What is QURE’s average 12-month price target, according to analysts?
Based on analyst ratings, uniQure N.V.’s 12-month average price target is 40.00.
What is QURE’s upside potential, based on the analysts’ average price target?
uniQure N.V. has 150.16% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is QURE a Buy, Sell or Hold?
uniQure N.V. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is uniQure N.V.’s price target?
The average price target for uniQure N.V. is 40.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $24.00. The average price target represents 150.16% Increase from the current price of $15.99.
The highest analyst price target is $70.00 ,the lowest forecast is $24.00. The average price target represents 150.16% Increase from the current price of $15.99.
What do analysts say about uniQure N.V.?
uniQure N.V.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of QURE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.